Technology & Data Science for Enhanced Patient Care

CMS Logo MSACL

Learning Center

Access additional learning opportunities.

UNITED STATES 2016

Help Us Reach Our Educational Support Goal of $40,000
Educational Travel Grants supported in part by:
MS3

Video Viewing Request

Video loading. Please wait...

Mass Spectrometry Quantification of Personalized Biomarkers for Multiple Myeloma
Melissa Hoffman
Moffitt Cancer Center/University of South Florida
[email protected]

Multiple Myeloma, an incurable disease with poor patient outcomes, is characterized by clonal expansion of the plasma cells in the bone marrow, which secrete a monoclonal immunoglobulin. This study utilizes a proteogenomics approach to develop individualized, peptide-based mass spectrometry assays to quantify each patient’s disease-specific biomarker. Personalized LC-MRM assays developed for variable region peptides using de novo RNA sequencing have shown a substantial increase in sensitivity compared to clinical methods. The increase in sensitivity improves minimal residual disease detection, which could improve patient outcomes.

Presented at MSACL 2016 US